xRead - September 2022

Wise et al.

Page 364

Author Manuscript Author Manuscript Author Manuscript Author Manuscript TABLE IX.B.1.c. Study

design Study groups Clinical endpoint Conclusion

improving rhinorrhea; comparable symptom and QOL improvement. rTNSS Comparable symptom improvement.

eye symptoms and QOL.

Olopatadine superior to placebo in reducing symptoms in children, improving QOL, and satisfying caregivers.

Olopatadine superior to placebo in reducing symptoms in children, improving QOL, and satisfying caregivers.

TNSS Both azelastine spray formulations superior to placebo; dose-response effect between dosages; no difference in bitter taste between formulations.

Kaliner et al. 1206 2009 1b DBRCT 1 Olopatadine 2.66 mg BID; rTNSS, rTOSS Both treatments improve symptoms; faster onset for olopatadine. Shah et al. 1207 2009 1b DBRCT 1 Azelastine 0.82 mg BID; 2 Azelastine 0.56 mg BID; 3 Placebo 2 Fluticasone 0.2 mg spray daily

TNSS Both azelastine doses superior to placebo; greater improvement with higher dose.

rTNSS, rTOSS, RQLQ Fluticasone superior to azelastine for rTNSS, rTOSS, PRQLQ, CGTSQ-AR

rTNSS, rTOSS, RQLQ Azelastine superior to placebo for nasal and TNSS, TOSS, PRQLQ, CGTSQ, SGA

1 Azelastine 0.28 mg BID;

2 Fluticasone propionate 0.1 mg spray BID

Han et al. 1200 2011 1b DBRCT 1 Azelastine 0.1% (dose not given); 2 Levocabastine hydrochloride 0.05% spray (dose not given) Howland et al. 1201 2011 1b DBRCT 1 Azelastine 0.82 mg BID; 2 Placebo Meltzer et al. 1202 2011 1b DBRCT 1 Olopatadine 1.33 mg BID; 2 Placebo

Berger et al. 1204 2009 1b DBRCT 1 Olopatadine 1.33 mg BID;

2 Olopatadine 2.66 mg BID; 3 Placebo

Bernstein et al. 1205 2009 1b DBRCT 1 Azelastine 0.28 mg BID;

2 Reformulated azelastine 0.28 mg BID; 3 Azelastine 0.56 mg BID;

4 Reformulated azelastine 0.56 mg BID; 5 Placebo 2 sprays

(post hoc

analysis)

Evidence for the role of topical intranasal antihistamines as monotherapy in the management of allergic rhinitis Study Year LOE Carr et al. 1199 2012 1b DBRCT

Int Forum Allergy Rhinol . Author manuscript; available in PMC 2020 June 10.